Streetbeat News

Revenues

RCL

Analysts have recently updated their ratings and price targets for Royal Caribbean Gr (NYSE:RCL), showing a generally positive outlook. Over the past quarter, 10 analysts offered diverse opinions, with the majority being bullish. The average 12-month price target is now $149.00, up from $136.56, indicating a 9.11% increase. Recent actions by analysts from firms like Wells Fargo, Stifel, and UBS have raised their price targets, reflecting optimism about the company's future performance. Royal Caribbean, a leading cruise company, has shown solid revenue growth of 27.96% as of December 31, 2023, but faces challenges in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 1:02 pm

OKTA

Recent analyst evaluations of Okta (NASDAQ:OKTA) show a mix of bullish and bearish perspectives with 18 analysts offering their ratings. The average 12-month price target is $85.67, reflecting a 1.81% increase from the previous target of $84.15. Analyst actions include both upgrades and downgrades, with price targets ranging from $70.00 to $110.00. Okta, a cloud-native security company, has shown impressive revenue growth and financial performance, despite lagging behind industry peers in revenue growth rate.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 1:01 pm

SVFD

Save Foods, Inc. (NASDAQ:SVFD), an Agri-Food Tech company, has commenced commercial activities in Brazil through an exclusive local distributor, following compliance with local regulations. This move capitalizes on Brazil's significant growth in fruit exports, which saw a 6% increase in 2023, reaching 1.06 million tons. Save Foods' eco crop protection solution aims to support Brazilian packers in meeting EU market standards, particularly the EU's residue limits. The partnership with the distributor is expected to enhance the post-harvest treatment of fresh produce, starting with limes and mangos, benefiting farmers, distributors, and consumers.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:01 pm

ASAN

Recent analysis of Asana (NYSE:ASAN) by 6 financial analysts shows a mixed sentiment, with the latest 12-month price targets suggesting an average target of $21.00, up from the previous $19.00. The ratings range from bullish to somewhat bearish, reflecting diverse perspectives on the company's performance and market position. Asana's financial indicators such as revenue growth, net margin, ROE, and ROA are discussed, highlighting both strengths and areas for improvement.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 1:00 pm

TDOC

Teladoc Health (NYSE:TDOC) has been analyzed by 7 analysts, showing a mix of ratings from bullish to bearish. The average 12-month price target is now $22.43, down 17.45% from the previous $27.17. Analysts have adjusted their ratings and price targets in response to market conditions and company performance. Teladoc Health, a virtual health provider, has shown impressive revenue growth and financial performance, despite a market capitalization below industry averages.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 1:00 pm

KRYS

Krystal Biotech announced a product revenue, net of $50.7 million for the year ended December 31, 2023, showcasing the company's financial performance.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:57 pm

SGRY

Surgery Partners projects its fiscal year 2024 revenue to exceed $3B, surpassing the consensus estimate of $2.99B. Additionally, the company anticipates its adjusted EBITDA to be greater than $495M.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:34 pm

CRGO

Freightos anticipates Q1 revenue to be between $5.2M-$5.3M, falling short of the estimated $7.025M. For FY24, the company expects revenue to range from $22.4M-$24.0M, below the forecast of $34.657M.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:28 pm

NBIX

VYGR

Voyager Therapeutics and Neurocrine Biosciences have selected a development candidate for Friedreich's Ataxia, triggering a $5M milestone payment to Voyager. Voyager is set to receive this payment in Q1 2024 and is eligible for future payments based on program advancement.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:15 pm

NTRA

The Centers For Medicare & Medicaid Services (CMS) has expanded coverage for Natera's Signatera Molecular Residual Disease Test to include ovarian cancer and neoadjuvant breast cancer. This decision broadens the potential patient base for Natera's diagnostic test, potentially increasing its usage and revenue from these additional cancer types.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:11 pm